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intramolecular epoxide allylation using allyl
carbonates†
Irene R. Márquez, Alba Millán, Araceli G. Campaña* and Juan M. Cuerva*
A useful method for the diastereoselective synthesis of vinyl substituted carbo- and heterocycles is
described. Highly functionalized structures difficult to achieve by other methodologies are obtained in a
single step by this procedure.
Epoxides are highly versatile functional groups in organic syn-
thesis owing to the fact that their manipulation yields many
attractive final products. Thus, for example, diverse carbon
nucleophiles, such as Grignard and organolithium reagents or
organocuprates, have been used in ring-opening reactions to
install a new C–C bond.1,2 The intramolecular version of this
reaction would allow the preparation of different carbo- and
heterocycles with different sizes and functionalities. Neverthe-
less, the synthesis of suitable polyfunctionalized starting
materials is not simple taking into account the chemical
incompatibilities between the required reactive partners. In
this context, neutral pronucleophiles like olefins or allylsilanes
(I, LG = SiR3, Scheme 1) are more convenient since they allow
better control of the reaction and functional group compatibil-
ity.3 A valuable advantage of the reactions of epoxides with
allylsilanes, compared with alkenes, is their ability to stabilize
β-carbocations (III, Scheme 1), thereby controlling which
carbon of the alkene is the nucleophilic carbon.4 Moreover the
allylsilane can control the direction of the final elimination
acting as a good leaving group that stabilizes the generated
positive charge (IV, Scheme 1). On the other hand, its main
drawback is related to the electrophilic character of the reac-
tion, which implies the use of Lewis acids, such as TiCl4, and
strict control over the temperature. Another disadvantage of
allylsilanes relative to simple alkenes is that extra synthetic
steps are necessary because they are generally prepared from
oxygenated-allyl groups. Therefore, the direct employment of
allylic oxygenated functionalities in epoxide ring-opening reac-
tions retaining the favourable characteristics of allyl silane
analogues using very mild reaction conditions would represent
an important advance in organic synthesis.
The limitation of this approach is that the corresponding
β-carbocations (Scheme 1, III, LG = OCOR) would not be stabi-
lized and the control of the direction of elimination would
remain a challenge due to the lack of a carbocation stabilizing
group and also a good leaving group. As a result, a cationic
pathway can be discarded in this case, and an alternative reac-
tion pathway based on carbon-centered radicals was con-
sidered. Cp2TiCl
5-mediated homolytic epoxide opening is a
well-known reaction,6–19 which has allowed many remarkable
transformations, including a highly successful bioinspired
approach to different natural products.20–26 Epoxyallylcarboxy-
lates I (LG = OCOR, Scheme 1) are expected to react with
Cp2TiCl, yielding radical intermediate type-V. After the
Scheme 1 Working hypothesis.
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homolytic opening of the epoxide, the β-titanoxy radical gener-
ated V would undergo further radical cyclization generating a
carbon-centered radical VI. At this point, we expected that an
oxygenated function in the β-position would act as a good
leaving group, thus directing the final elimination towards IV
assisted by Cp2TiCl as the Lewis acid.
27,28 In fact, we had pre-
viously observed the Cp2TiCl-mediated radical fragmentation of
β-acetoxy alkyl radicals toward the corresponding alkenes.21,29
In this alternative radical pathway, Cp2TiCl would play a
crucial dual role in the intramolecular epoxide allylation with
oxygenated-allyl groups: (i) starting the reaction by homolytic
opening of the oxirane ring and (ii) controlling the final
product obtained by radical fragmentation.
Here we wish to communicate that epoxides can formally
be allylated intramolecularly in a highly diastereoselective
manner under smooth reaction conditions using easily pre-
pared and handled allylic carbonates as allylation reagents.
This approach also allows the preparation of different carbo-
and heterocycles with different functionalities.
Due to the known oxophilic character of Ti(III), our initial
studies began testing different allyl pronucleophiles 1a–d and
3, including different oxygenated functional groups such as
carbonate, acetate, benzoate, methoxyl or hydroxyl groups.
Moreover, an epoxyallylsilane 6 was also tested in order to
compare the observed results with oxygenated functions.
Remarkably, the new developments in titanocene(III)-regenerat-
ing agents now allow the use of substoichiometric amounts of
Cp2TiCl2 as a precatalyst. In this context, the combination of
2,4,6-collidine and trimethylsilyl chloride developed in our lab30
has been extensively used, and it was the choice in this case.
Treatment of compounds 1a–d with Cp2TiCl led to the
expected cyclic compound 2 with variable yields from 50 to 85%
(Scheme 2). It is noteworthy that compound 2 was obtained as a
single diastereomer in all cases. NOE-diff. experiments (see the
Experimental section) showed a cis relationship between the
hydroxyl group at C-3 and the vinyl group at C-5.
When epoxyallylic alcohol 3 was treated with Cp2TiCl, cyclic
compounds 4 and 5 were isolated in a 2/1 ratio (Scheme 3). In
this case, the lack of a better leaving group resulted in a
different final process. After homolytic oxirane-opening and
subsequent cyclization, Ti(III)-mediated hydrogen abstraction
in the radical intermediate yields aldehyde 4 (Scheme 3,
process a).31 Besides, the radical intermediate can abstract a
hydrogen-atom from the solvent (THF) leading to reduced
product 5 (Scheme 3, process b).32
Silyl derivative 6 was assayed under the same reaction con-
ditions, leading to a mixture of trimethylsilyl containing com-
pounds 7 and 8 in a 1/0.6 ratio (Scheme 4).23 These two
compounds were obtained by similar hydrogen-atom abstrac-
tions mentioned above. Ethyl carbonate derivative 1a (85% yield,
Scheme 2) resulted in the best yield and therefore ethyl carbon-
ate was the leaving group of choice for the following reactions.
With the optimized conditions in hand, we explored sub-
strates with different linkers, functionalities and substitution
patterns. The results are summarized in Table 1.
The reaction successfully gave different five- and six-mem-
bered carbo- and heterocycles with excellent diastereoselectiv-
ities in almost all the tested substrates. Titanium-induced
cyclization of compound E-1a (Table 1, entry 1) led to com-
pound 2 as Z-1a (Scheme 2), revealing the stereoconvergent
nature of the process. Additionally, the reaction proved to be
compatible with different functional groups, including esters
(Table 1, entries 1–7 and 11–12), sulfones (Table 1, entry 10),
sulphonamides (Table 1, entries 8 and 9) or free hydroxyl
groups (Table 1, entry 11), and permitted different substitution
patterns in the oxirane ring (Table 1, entries 1–4) as well as in
the involved alkene (Table 1, entries 5 and 11).
Scheme 2 Ti(III)-mediated cyclization of model compounds 1a–d.
Reaction conditions: (i) 1a–d (1.0 mmol) Cp2TiCl2 (0.2 mmol), Mn
(8.0 mmol), Me3SiCl (4.0 mmol), 2,4,6-collidine (6.0 mmol), THF, RT,
16 h. Isolated yields after column chromatography.
Scheme 3 Ti(III)-mediated cyclization of compound 3. Reaction con-
ditions: (i) 3 (1.0 mmol) Cp2TiCl2 (0.2 mmol), Mn (8.0 mmol), Me3SiCl
(4.0 mmol), 2,4,6-collidine (6.0 mmol), THF, RT, 16 h. Isolated yields
after column chromatography.
Scheme 4 Ti(III)-mediated cyclization of compound 6. Reaction con-
ditions: (i) 6 (1.0 mmol) Cp2TiCl2 (0.2 mmol), Mn (8.0 mmol), Me3SiCl
(4.0 mmol), 2,4,6-collidine (6.0 mmol), THF, RT, 16 h. Isolated yield after
column chromatography. Compounds 7 and 8 were not separated.
Research Article Organic Chemistry Frontiers
























































































The regiochemistry of the radical epoxide opening mainly
depends upon the substitution pattern33 and controls the size
of the obtained final cycle (Table 1, entries 1 vs. 2 and entries
8 vs. 9). As shown in entry 4, treatment of compound 13 with
Cp2TiCl led to the formation of a 1/1 mixture of five- and six-
membered rings, as expected from a 1,2-disubstituted oxirane
ring.8,9 However in compound 18 electronic effects control the
homolytic epoxide opening, thus only affording the six-mem-
bered ring 19. Stereoconvergency was further demonstrated, as
diastereomeric mixture 28 (entry 11) gave rise to a single cyclic
diastereomer 29. It is also noteworthy that the stereoselectivity





















a Isolated yield after column chromatography. b 7/3 mixture of cis/trans
diastereoisomers. c Compounds 14 and 15 were obtained in a 1/1 ratio.
Both compounds were obtained as diastereomeric mixture in 2/1 dr.
d Additional 12% of cyclic compound S43 in which the carbonate
group is eliminated was also obtained (see ESI for further details).
e 1/1 mixture of cis/trans diastereoisomers. f Additional 15% of
cyclic compound S44 in which the carbonate moiety is eliminated was
also obtained (see ESI for further details).
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of this cyclization allows the setting up of two stereocenters in
six-membered and notably five-membered rings (entries 2 and
9). When the stereocenters are located in 1,3-relative positions
a cis stereochemistry between the hydroxyl group at C-3 and
the vinyl group at C-5 is observed as in the case of compounds
2, 17 and 23 (entries 1, 5 and 8). On the other hand, com-
pounds presenting contiguous stereocenters showed a trans
(entries 2, 7, 9 and 12) or cis relationship (entry 3) between the
vinyl and hydroxymethyl groups depending on the substitution
pattern of the intermediate radical. Interestingly, in more func-
tionalized substrates even three stereocenters can be allocated
stereoselectively (entries 6 and 11). In the case of 1,3-relative
positions, cis stereochemistry between the hydroxyl group at
C-3 and the vinyl group at C-5 is preserved. The additional
stereocenter at C-4 presents a trans stereochemistry with
respect to the other two stereocenters.
All these stereochemical findings can be rationalized invok-
ing the Beckwith–Houk rules.34,35 cis Substituted five-membered
rings are expected for 5-exo-trig cyclizations (entry 3). Trisubsti-
tuted radicals proceed disposing the bulkier substituent (R2 in
Scheme 5a) in a pseudoequatorial position (Scheme 5) thus
yielding the observed cyclopentanes 10 and 25 (entries 2 and 9).
Although cyclizations of 6-heptenyl radicals are less
studied, a similar reasoning explains the experimental results.
In the chair-like transition states all the bulkier substituents
(R1 and R3 in Scheme 6) are disposed in the equatorial posi-
tions. Additional template effects cannot be ruled out in cycli-
zation of compound 28 (entry 11).20–23
In the case of entries 4 and 10, the structures of compounds
13 and 26 do not follow these stereochemical trends and
mixtures of diastereoisomers are obtained. The intrinsic reac-
tivity of a 1,2-disubstituted epoxide in compound 13 (entry 4)
precludes a clear analysis of its stereoselectivity. In compound
26 (entry 10), the transition state may be affected by bulky
phenyl sulphonyl groups avoiding a clear chair-like transition
state and leading to the formation of both isomers.
Conclusions
A useful method for the diastereoselective synthesis of vinyl
substituted carbo- and heterocycles is presented. The protocol
is based on the radical opening of an epoxide and subsequent
intramolecular addition to an allyl carbonate. Formally, the
reaction yields similar products as the allylation of epoxides by
the appropriate nucleophile but with several significant advan-
tages. Firstly, the polyfunctionalized substrates required are
very easily obtained and handled. Secondly, the cyclization
reaction occurs at room temperature and under very smooth
conditions highly compatible with diverse functional groups.
And lastly, the diastereoselectivity observed is quite remark-
able giving rise in most of the cases to a single diastereomer
even when three stereogenic centres are generated in the final
product. Highly functionalized structures difficult to achieve
by other methodologies are obtained in a single step by this
procedure. Thus, this method is an interesting tool in the
context of organic synthesis.
Experimental section
General remarks
Unless otherwise stated, all reagents and solvents (CH2Cl2,
Et2O, MeCN, EtOAc, hexane, DMF, and MeOH) were purchased
from commercial sources and used without further purifi-
cation. Dry THF was freshly distilled over Na/benzophenone.
Flash column chromatography was carried out using Silica Gel
60 (230–400 mesh, Scharlab, Spain) as the stationary phase.
Analytical TLC was performed on aluminium sheets coated
with silica gel with the fluorescent indicator UV254 (Alugram
SIL G/UV254, Mackerey-Nagel, Germany) and observed under
UV light (254 nm) and/or staining with Ce/Mo reagent or phos-
phomolybdic acid solution and subsequent heating. All 1H
and 13C NMR spectra were recorded on Varian 300, 400 or
500 MHz spectrometers at a constant temperature of 298 K.
Chemical shifts are reported in ppm and referenced to residual
solvent. Coupling constants ( J) are reported in hertz (Hz). Stan-
dard abbreviations indicating multiplicity were used as
follows: m = multiplet, quint. = quintet, q = quartet, t = triplet,
d = doublet, s = singlet, b = broad. Assignment of the 13C NMR
multiplicities was accomplished by DEPT techniques.
Characterization data of substrates Z-1a, 1b–d, E-1a, 3, 6, 9, 11,
13, 16, 18, 20, 22, 24, 26, 28 and 30
Compound Z-1a. 1H-NMR (300 MHz, CDCl3) δ(ppm):
5.75–5.59 (m, 1H), 5.59–5.43 (m, 1H), 4.64 (d, J = 6.7 Hz, 2H),
Scheme 5 (a) Ring-closure of 5-hexenyl radicals. (b) Selected examples
from Table 1.
Scheme 6 (a) Schematic ring-closure of 6-heptenyl radicals. (b)
Selected examples from Table 1.
Research Article Organic Chemistry Frontiers
























































































4.15 (q, J = 7.0 Hz, 3H), 3.71 (s, 3H), 3.70 (s, 3H), 2.80 (d, J =
7.5 Hz, 2H), 2.70 (dd, J = 7.3, 4.2 Hz, 1H), 2.21 (dd, J = 14.8,
4.2 Hz, 1H), 1.95 (dd, J = 14.8, 7.3 Hz, 1H), 1.27 (t, J = 7.0 Hz,
3H), 1.24 (s, 3H), 1.20 (s, 3H). 13C-NMR (75 MHz, CDCl3)
δ(ppm): 171.1 (C), 171.0 (C), 155.1 (C), 128.3 (CH), 127.2 (CH),
64.1 (CH2), 63.2 (CH2), 59.8 (C), 57.9 (C), 56.4 (C), 52.8 (CH3),
52.7 (CH3), 32.5 (CH2), 31.6 (CH2), 24.7 (CH3), 18.8 (CH3), 14.3
(CH3). HRMS (TOF MS ES+) m/z calcd for C17H26O8 [M + Na]
+:
381.1519, found: 381.1525.
Compound 1b. 1H-NMR (300 MHz, CDCl3) δ(ppm):
5.70–5.55 (m, 1H), 5.55–5.40 (m, 1H), 4.57 (d, J = 6.6 Hz, 1H),
3.70 (s, 3H), 3.68 (s, 3H), 2.78 (d, J = 7.5 Hz, 2H), 2.68 (dd, J =
7.3, 4.3 Hz, 1H), 2.19 (dd, J = 14.9, 4.3 Hz, 1H), 1.99 (s, 3H),
2.00–1.89 (m, 1H), 1.23 (s, 3H), 1.19 (s, 3H). 13C-NMR (75 MHz,
CDCl3) δ(ppm): 171.1 (C), 170.8 (C), 127.7 (CH), 60.1 (CH2), 59.8
(CH), 57.9 (C), 56.3 (C), 52.8 (CH3), 52.6 (CH3), 32.3 (CH2), 31.4
(CH2), 24.6 (CH3), 20.9 (CH3), 18.7 (CH3). HRMS (TOF MS ES+)
m/z calcd for C16H24O7Na [M + Na]
+: 351.1414, found: 351.1415.
Compound 1c. 1H-NMR (300 MHz, CDCl3) δ(ppm): 8.00 (d, J
= 7.4 Hz, 2H), 7.52 (t, J = 7.4 Hz, 1H), 7.40 (t, J = 7.4 Hz, 2H),
5.87–5.71 (m, 1H), 5.64–5.50 (m, 1H), 4.86 (d, J = 6.7 Hz, 2H),
3.73 (s, 3H), 3.71 (s, 3H), 2.89 (d, J = 7.5 Hz, 2H), 2.74 (dd, J =
7.4, 4.1 Hz, 1H), 2.25 (dd, J = 14.8, 4.1 Hz, 1H), 2.08–1.94 (m,
1H), 1.24 (s, 3H), 1.21 (s, 3H). 13C-NMR (75 MHz, CDCl3)
δ(ppm): 171.2 (C), 171.1 (C), 166.4 (C), 133.0 (CH), 130.2 (C),
129.6 (CH), 128.4 (CH), 128.0 (CH), 127.8 (CH), 60.6 (CH2),
59.9 (CH), 58.0 (C), 56.4 (C), 52.8 (CH3), 52.7 (CH3), 32.4 (CH2),
31.6 (CH2), 24.7 (CH3), 18.8 (CH3). HRMS (TOF MS ES+) m/z
calcd for C21H26O7Na [M + Na]
+: 413.1570, found: 413.1569.
Compound 1d. 1H-NMR (300 MHz, C6D6) δ(ppm): 5.85–5.68
(m, 1H), 5.60–5.43 (m, 1H), 3.86 (d, J = 6.3 Hz, 2H), 3.39 (s,
3H), 3.36 (s, 3H), 3.06 (s, 3H), 3.09–3.02 (m, 2H), 2.87 (dd, J =
8.0, 3.8 Hz, 1H), 2.45 (dd, J = 14.8, 3.8 Hz, 1H), 2.20 (dd, J =
14.8, 8.0 Hz, 1H), 1.05 (s, 3H), 1.03 (s, 3H). 13C-NMR (75 MHz,
CDCl3) δ(ppm): 171.2 (C), 171.1 (C), 130.4 (CH), 125.9 (CH),
67.9 (CH2), 59.8 (CH), 58.0 (CH3), 57.9 (C), 56.3 (C), 52.7 (CH3),
52.6 (CH3), 32.2 (CH2), 31.5 (CH2), 24.6 (CH3), 18.7 (CH3).
HRMS (TOF MS ES+) m/z calcd for C15H24O6Na [M + Na]
+:
323.1465, found: 323.1474.
Compound 3. 1H-NMR (300 MHz, C6D6) δ(ppm): 5.84–5.68
(m, 1H), 5.51–5.34 (m, 1H), 4.21–4.06 (m, 1H), 4.06–3.91 (m,
1H), 3.36 (s, 3H), 3.34 (s, 3H), 3.12 (dd, J = 14.8, 8.5 Hz, 1H),
2.98 (dd, J = 14.8, 6.8 Hz, 1H), 2.80 (dd, J = 8.3, 3.2 Hz, 1H),
2.48 (dd, J = 14.9, 3.2 Hz, 1H), 2.12 (dd, J = 14.9, 8.3 Hz, 1H),
1.00 (s, 3H), 0.99 (s, 3H). 13C-NMR (75 MHz, C6D6) δ(ppm):
171.5 (C), 171.3 (C), 134.0 (CH), 125.0 (CH), 60.1 (CH), 58.1
(CH2), 57.7 (C), 57.1 (C), 52.4 (CH3), 52.3 (CH3), 32.8 (CH2),
31.6 (CH2), 24.5 (CH3), 18.6 (CH3). HRMS (TOF MS ES+) m/z
calcd for C14H22O6Na [M + Na]
+: 309.1308, found: 309.1307.
Compound 6. 1H-NMR (300 MHz, CDCl3) δ(ppm): 5.62–5.45
(m, 1H), 5.18–5.01 (m, 1H), 3.74 (s, 3H), 3.73 (s, 3H), 2.80–2.72
(m, 1H), 2.71 (d, J = 7.0 Hz, 2H), 2.20 (dd, J = 14.8, 4.6 Hz, 1H),
2.00 (dd, J = 14.8, 7.3 Hz, 1H), 1.42 (d, J = 8.0 Hz, 2H), 1.28 (s,
3H), 1.24 (s, 3H), −0.02 (s, 9H). 13C-NMR (75 MHz, CDCl3)
δ(ppm): 171.6 (C), 132.0 (CH), 121.3 (CH), 60.1 (CH), 58.0 (C),
56.8 (C), 52.6 (CH3), 52.5 (CH3), 36.9 (CH2), 32.0 (CH2), 24.8
(CH3), 23.1 (CH3), 18.8 (CH3), −1.9 (CH3). HRMS (TOF MS ES+)
m/z calcd for C17H31O5Si [M + H]
+: 343.1941, found: 343.1951.
Compound E-1a. 1H-NMR (300 MHz, acetone) δ(ppm):
5.75–5.65 (m, 2H), 4.69 (d, J = 6.4 Hz, 2H, Z-isomer), 4.54 (d,
J = 6.4 Hz, 2H, E-isomer), 4.19 (q, J = 7.1 Hz, 2H), 3.75 (s, 3H),
3.73 (s, 3H), 2.84 (d, J = 7.2 Hz, 2H, Z-isomer), 2.81–2.69 (m,
3H), 2.22 (dd, J = 14.9, 4.2 Hz, 1H), 1.99 (dd, J = 14.9, 7.6 Hz,
1H), 1.30 (t, J = 7.1 Hz, 3H), 1.28 (s, 3H), 1.25 (s, 3H). 13C-NMR
(75 MHz, CDCl3) δ(ppm): 171.0 (C), 170.9 (C), 154.8 (C), 129.7
(CH), 128.4 (CH), 67.5 (CH2), 63.9 (CH2), 59.7 (CH), 57.8 (C),
56.5 (CH), 52.6 (CH3), 52.5 (CH3), 36.2 (CH2), 32.2 (CH2), 24.6
(CH3), 18.7 (CH3), 14.2 (CH3). HRMS (TOF MS ES+) m/z calcd
for C17H26O8Na [M + Na]
+: 381.1519, found: 381.1516.
Compound 9. 1H-NMR (300 MHz, C6D6) δ(ppm): 5.74–5.46
(m, 2H), 4.63 (d, J = 5.7 Hz, 2H), 3.91 (q, J = 7.1 Hz, 2H), 3.35
(s, 6H), 3.00–2.89 (m, 2H), 2.31 (d, J = 3.9 Hz, 2H), 2.26 (d, J =
5.1 Hz, 1H), 2.11 (d, J = 5.1 Hz, 1H), 1.10 (s, 3H), 0.93 (t, J =
7.1 Hz, 3H). 13C-NMR (75 MHz, C6D6) δ(ppm): 171.2 (C), 171.0
(C), 155.5 (C), 128.9 (CH), 127.4 (CH), 63.7 (CH2), 63.1 (CH2),
56.7 (C), 54.0 (CH2), 53.9 (C), 52.2 (CH3), 52.2 (CH3), 39.9 (CH2),
32.1 (CH2), 21.6 (CH3), 14.2 (CH3). HRMS (TOF MS ES+) m/z
calcd for C16H24O8Na [M + Na]
+: 367.1363, found: 367.1372.
Compound 11. 1H-NMR (300 MHz, C6D6) δ(ppm): 5.69–5.54
(m, 1H), 5.56–5.38 (m, 1H), 4.61 (d, J = 6.7 Hz, 2H), 3.90 (q, J =
7.1 Hz, 2H), 3.35 (s, 3H), 3.33 (s, 3H), 2.93 (d, J = 7.8 Hz, 2H),
2.87–2.76 (m, 1H), 2.33–2.20 (m, 2H), 1.98 (dd, J = 5.2, 2.4 Hz,
1H), 1.88 (dd, J = 14.7, 7.8 Hz, 1H), 0.90 (t, J = 7.1 Hz, 3H).
13C-NMR (75 MHz, C6D6) δ(ppm): 171.0 (C), 170.9 (C), 155.5
(C), 128.5 (CH), 127.8 (CH), 63.8 (CH2), 63.1 (CH2), 56.7 (CH2),
52.3 (CH3), 48.2 (CH), 46.0 (CH2), 36.8 (CH2), 31.9 (CH2), 14.2
(CH3). HRMS (TOF MS ES+) m/z calcd for C15H22O8Na
[M + Na]+: 353.1206, found: 353.1197.
Compound 13. 5.69–5.56 (m, 1H), 5.56–5.41 (m, 1H), 4.61
(d, J = 6.9 Hz, 2H), 3.89 (q, J = 7.1 Hz, 2H), 3.36 (s, 3H), 3.34 (s,
3H), 2.94 (d, J = 7.8 Hz, 2H), 2.76–2.68 (m, 1H), 2.44–2.34 (m,
1H), 2.28 (dd, J = 14.6, 4.2 Hz, 1H), 2.02 (dd, J = 14.6, 7.4 Hz,
1H), 0.96 (d, J = 5.2 Hz, 3H), 0.90 (t, J = 7.1 Hz, 3H). 13C-NMR
(75 MHz, C6D6) δ(ppm): 170.9 (C), 155.0 (C), 128.2 (CH), 127.2
(CH), 64.0 (CH2), 63.1 (CH2), 56.2 (C), 55.4 (CH), 54.3 (CH),
52.8 (CH3), 52.7 (CH3), 35.9 (CH2), 31.6 (CH2), 17.3 (CH3), 14.3
(CH3). HRMS (TOF MS ES+) m/z calcd for C16H24O8 [M + Na]
+:
367.1363, found: 367.1377.
Compound 16. 1H-NMR (300 MHz, CDCl3) δ(ppm): 5.56 (t,
J = 7.0 Hz, 1H), 4.40 (s, 2H), 3.93 (q, J = 7.1 Hz, 2H), 3.38 (s,
3H), 3.36 (s, 3H), 3.00 (t, J = 7.0 Hz, 2H), 2.86 (dd, J = 7.9,
4.1 Hz, 1H), 2.43 (dd, J = 14.8, 4.1 Hz, 1H), 2.20 (dd, J = 14.8,
7.9 Hz, 1H), 1.51 (s, 3H), 1.05 (s, 3H), 1.04 (s, 3H), 0.93 (t, J =
7.1 Hz, 3H). 13C-NMR (75 MHz, CDCl3) δ(ppm): 171.4 (C),
171.2 (C), 155.4 (C), 134.4 (C), 122.9 (CH), 72.6 (CH2), 63.7
(CH2), 59.7 (CH), 57.3 (C), 56.8 (C), 52.3 (CH3), 52.2 (CH3), 32.9
(CH2), 32.1 (CH2), 24.6 (CH3), 18.7 (CH3), 14.2 (CH3), 13.9
(CH3). HRMS (TOF MS ES+) m/z calcd for C18H28O8Na
[M + Na]+: 395.1676, found: 395.1667.
Compound 18. 1H-NMR (300 MHz, CDCl3) δ(ppm):
7.36–7.25 (m, 3H), 7.26–7.16 (m, 2H), 5.78–5.61 (m, 2H), 4.52
(d, J = 4.5 Hz, 2H), 4.16 (q, J = 7.1 Hz, 2H), 3.73 (s, 3H), 3.69 (s,
Organic Chemistry Frontiers Research Article
























































































3H), 3.56 (d, J = 1.8 Hz, 1H), 2.96 (ddd, J = 6.7, 5.0, 1.8 Hz, 1H),
2.77 (d, J = 5.7 Hz, 2H), 2.27 (dd, J = 14.7, 5.0 Hz, 1H), 2.14 (dd,
J = 14.7, 6.7 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H). 13C-NMR (75 MHz,
CDCl3) δ(ppm): 170.9 (C), 154.9 (C), 136.9 (C), 129.6 (CH),
128.6 (CH), 128.5 (CH), 128.3 (CH), 125.6 (CH), 67.5 (CH2),
64.0 (CH2), 58.8 (CH), 58.5 (CH), 56.4 (C), 52.8 (CH3), 36.7
(CH2), 36.2 (CH2), 14.3 (CH3). HRMS (TOF MS ES+) m/z calcd
for C21H26O8Na [M + Na]
+: 429.1519, found: 429.1529.
Compound 20. 1H-NMR (300 MHz, CDCl3) δ(ppm):
5.76–5.59 (m, 2H), 4.54 (d, J = 4.5 Hz, 2H), 4.19 (q, J = 7.1 Hz,
2H), 3.72 (s, 6H), 2.95–2.85 (m, 1H), 2.79–2.70 (m, 1H), 2.65 (d,
J = 5.5 Hz, 2H), 2.51–2.42 (m, 1H), 2.11–1.91 (m, 2H), 1.54–1.38
(m, 2H), 1.30 (t, J = 7.1 Hz, 3H). 13C-NMR (75 MHz, CDCl3)
δ(ppm): 171.1 (C), 154.9 (C), 129.7 (CH), 128.1 (CH), 67.5 (CH2),
63.9 (CH2), 57.1 (C), 52.5 (CH3), 51.7 (CH), 46.9 (CH2), 35.9
(CH2), 28.9 (CH2), 27.3 (CH2), 14.2 (CH3). HRMS (TOF MS ES+)
m/z calcd for C16H24O8Na [M + Na]
+: 367.1363, found: 367.1362.
Compound 22. 1H-NMR (300 MHz, CDCl3) δ(ppm): 7.71 (d,
J = 8.3 Hz, 2H), 7.31 (d, J = 8.3 Hz, 2H), 5.79–5.64 (m, 1H),
5.64–5.51 (m, 1H), 4.68 (d, J = 6.7 Hz, 2H), 4.18 (q, J = 7.1 Hz,
2H), 4.09–3.90 (m, 2H), 3.65 (dd, J = 14.8, 3.7 Hz, 1H), 2.95 (dd,
J = 14.8, 5.7 Hz, 1H), 2.87 (dd, J = 5.7, 3.7 Hz, 1H), 2.43 (s, 3H),
1.29 (t, J = 7.1 Hz, 3H), 1.28 (s, 3H), 1.24 (s, 3H). 13C-NMR
(75 MHz, CDCl3) δ(ppm): 154.9 (C), 143.6 (C), 136.6 (C), 129.8
(CH), 129.6 (CH), 127.2 (CH), 127.1 (CH), 64.1 (CH2), 62.7
(CH2), 61.9 (CH), 57.8 (C), 47.1 (CH2), 45.3 (CH2), 24.4 (CH3),
21.5 (CH3), 18.8 (CH3), 14.2 (CH3). HRMS (TOF MS ES+) m/z
calcd for C19H28NO6S [M + H]
+: 398.1637, found: 398.1627.
Compound 24. 1H-NMR (300 MHz, C6D6) δ(ppm): 7.65 (d,
J = 8.2 Hz, 2H), 6.78 (d, J = 8.2 Hz, 2H), 5.55–5.34 (m, 2H), 4.63
(d, J = 6.2 Hz, 2H), 3.91 (d, J = 6.1 Hz, 2H), 3.88 (q, J = 7.1 Hz,
2H), 3.35 (d, J = 14.5 Hz, 1H), 2.79 (d, J = 14.5 Hz, 1H), 2.25 (d,
J = 4.8 Hz, 1H), 2.10 (d, J = 4.8 Hz, 1H), 1.90 (s, 3H), 1.20 (s,
3H), 0.90 (t, J = 7.1 Hz, 3H). 13C-NMR (75 MHz, acetone)
δ(ppm): 155.7 (C), 144.4 (C), 138.2 (C), 130.7 (CH), 130.1 (CH),
128.1 (CH), 127.9 (CH), 64.4 (CH2), 63.5 (CH2), 56.2 (CH2), 53.6
(CH), 51.9 (CH2), 46.3 (CH2), 21.5 (CH3), 19.2 (CH3), 14.6
(CH3). HRMS (TOF MS ES+) m/z calcd for C18H26NO6S
[M + H]+: 384.1481, found: 384.1476.
Compound 26. 1H-NMR (300 MHz, C6D6) δ(ppm): 8.22–8.11
(m, 4H), 7.09–6.93 (m, 6H), 6.08 (dt, J = 11.0, 6.5 Hz, 1H), 5.55
(dt, J = 11.0, 6.6 Hz, 1H), 4.43 (d, J = 6.8 Hz, 2H), 3.88 (q, J =
7.1 Hz, 2H), 3.49 (t, J = 4.9 Hz, 1H), 3.36 (d, J = 6.5 Hz, 2H),
2.81 (dd, J = 16.1, 4.9 Hz, 1H), 2.50 (dd, J = 16.1, 4.9 Hz, 1H),
1.16 (s, 3H), 1.02 (s, 3H), 0.91 (t, J = 7.1 Hz, 3H). 13C-NMR
(75 MHz, C6D6) δ(ppm): 155.4 (C), 137.4 (C), 137.2 (C), 134.6
(CH), 134.5 (CH), 132.0 (CH), 131.9 (CH), 128.8 (CH), 128.7
(CH), 127.6 (CH), 126.8 (CH), 89.8 (C), 63.9 (CH2), 62.8 (CH2),
58.7 (CH), 58.5 (C), 30.6 (CH2), 28.9 (CH2), 24.5 (CH3), 18.8
(CH3), 14.2 (CH3). HRMS (TOF MS ES+) m/z calcd for
C25H30O8S2Na [M + Na]
+: 545.1274, found: 545.1260.
Compound 28. 1H-NMR (300 MHz, CDCl3) δ(ppm): 5.31 (t,
J = 7.3 Hz, 1H), 4.42 (s, 2H), 4.13 (q, J = 7.1 Hz, 2H), 3.69 (s,
3H), 3.68 (s, 3H), 3.57 (s, 2H), 2.80 (dd, J = 6.9, 5.2 Hz, 1H),
2.71 (d, J = 7.3 Hz, 2H), 2.19 (dd, J = 14.9, 5.2 Hz, 1H), 2.03 (dd,
J = 14.9, 6.9 Hz, 1H), 1.63 (s, 3H), 1.30 (s, 3H), 1.24 (t, J = 7.1
Hz, 3H). 13C-NMR (75 MHz, CDCl3) δ(ppm): 171.3 (C), 171.2
(C), 155.0 (C), 134.1 (C), 122.6 (CH), 72.7 (CH2), 64.0 (CH2),
63.5 (CH2), 60.6 (CH), 60.4 (C), 56.3 (C), 52.8 (CH3), 52.7 (CH3),
32.0 (CH2), 31.6 (CH2), 19.9 (CH3), 14.2 (CH3), 14.0 (CH3).
HRMS (TOF MS ES+) m/z calcd for C18H28O9Na [M + Na]
+:
411.1625, found: 411.1624.
Compound 30. 1H-NMR (300 MHz, CDCl3) δ(ppm):
5.72–5.59 (m, 1H), 5.53–5.40 (m, 1H), 4.61 (d, J = 6.8 Hz, 2H),
4.14 (q, J = 7.1 Hz, 2H), 3.67 (s, 6H), 2.65 (d, J = 7.6 Hz, 2H),
2.53 (dd, J = 11.9, 4.7 Hz, 2H), 1.92 (t, J = 8.3 Hz, 2H), 1.51–1.31
(m, 2H), 1.26 (t, J = 7.1 Hz, 3H), 1.25 (s, 3H). 13C-NMR
(75 MHz, CDCl3) δ(ppm): 171.2 (C), 155.0 (C), 128.3 (CH),
127.0 (CH), 64.0 (CH2), 63.0 (CH2), 57.0 (C), 56.4 (C), 53.5
(CH2), 52.6 (CH3), 31.3 (CH2), 30.8 (CH2), 28.2 (CH2), 20.8
(CH3), 14.3 (CH3). HRMS (TOF MS ES+) m/z calcd for C17H27O8
[M + H]+: 359.1706, found: 359.1719.
General procedure for the intramolecular epoxide allylation
Rigorously deoxygenated dry THF (10 mL) was added to a pre-
viously deoxygenated mixture of Cp2TiCl2 (0.2 mmol) and Mn
(8.0 mmol) under an Ar atmosphere, and the suspension was
stirred at room temperature until it turned green (about
10 min). A solution of the previously synthesized polyfunctio-
nalized substrate (1.0 mmol) in THF (2 mL), Me3SiCl
(4.0 mmol) and 2,4,6-collidine (6.0 mmol) was then added.
The reaction mixture was stirred at room temperature for 16 h
and then diluted with EtOAc, washed with HCl (10%), dried
over anhydrous Na2SO4 and the solvent removed. The residue
was subjected to flash column chromatography (SiO2, EtOAc–
hexane mixtures) to give the corresponding cyclic products.
Characterization data of cyclic products 2, 4, 5, 7, 8, 10, 12, 14,
15, 17, 19, 21, 23, 25, 27, 29, and 31
(See ESI† for numbering and copies of 1H-NMR and 13C-NMR
spectra.)
Compound 2. Colorless oil; 65–85% yield. 1H-NMR
(500 MHz, CDCl3) δ(ppm): 5.69 (ddd, J = 17.2, 10.4, 8.1 Hz,
1H), 5.06 (dd, J = 10.4, 1.8 Hz, 1H), 5.03 (d, J = 17.2 Hz, 1H),
3.74 (s, 3H), 3.69 (s, 3H), 3.40 (dd, J = 12.1, 4.2 Hz, 1H), 2.37
(ddd, J = 12.1, 4.2, 2.4 Hz, 1H), 2.10 (dt, J = 13.6, 2.7 Hz, 1H),
1.90 (ddd, J = 12.7, 8.1, 2.7 Hz, 1H), 1.82 (t, J = 12.7 Hz, 1H),
1.80 (t, J = 13.2 Hz, 1H), 0.95 (s, 3H), 0.77 (s, 3H); NOE-diff.
experiment: proton irradiated, (NOEs observed): H-7, (H2-8,
H-5), H-3, (H-2b H-5). 13C-NMR (75 MHz, CDCl3) δ(ppm): 171.9
(C), 171.5 (C), 137.7 (CH), 116.6 (CH2), 74.4 (CH), 54.9 (C), 52.9
(CH3), 52.8 (CH3), 47.0 (CH), 38.0 (C), 34.7 (CH2), 31.9 (CH2),
25.6 (CH3), 12.3 (CH3). HRMS (TOF MS ES+) m/z calcd for
C14H22O5Na [M + Na]
+: 293.1359, found: 293.1351.
Compound 4. Colorless oil; 40% yield. 1H-NMR (500 MHz,
CDCl3) δ(ppm): 9.74 (s, 1H), 3.77 (s, 3H), 3.69 (s, 3H), 3.46 (dd,
J = 11.9, 3.8 Hz, 1H), 2.57 (dd, J = 16.8, 2.4 Hz, 1H), 2.39 (ddd,
J = 13.2, 4.0, 2.3 Hz, 1H), 2.17 (dd, J = 10.0, 2.9 Hz, 1H), 2.12
(dt, J = 13.2, 3.5 Hz, 1H), 1.97–1.86 (m, 1H), 1.80 (t, J = 12.6 Hz,
1H), 1.61 (t, J = 13.4 Hz, 1H), 0.99 (s, 3H), 0.77 (s, 3H); NOE-
diff. experiment: proton irradiated (NOEs observed): H-7a
(H-7b, H-5), H-3 (H-2a, H-5), H-2a (H-2b, H-3). 13C-NMR
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(125 MHz, CDCl3) δ(ppm): 201.8 (C), 171.5 (C), 171.2 (C), 73.9
(CH), 54.7 (C), 53.0 (CH2), 52.9 (CH2), 44.6 (CH2), 38.0 (C), 36.5
(CH), 34.7 (CH2), 32.5 (CH2), 25.1 (CH3), 12.4 (CH3). HRMS
(TOF MS ES+) m/z calcd for C14H22O6Na [M + Na]
+: 309.1308,
found: 309.1308.
Compound 5. Colorless oil; 23% yield. 1H-NMR (400 MHz,
CDCl3) δ(ppm): 3.75 (s, 3H), 3.71 (s, 3H), 3.71–3.57 (m, 2H),
3.34 (dd, J = 11.8, 4.0 Hz, 1H), 2.39 (ddd, J = 13.2, 3.9, 2.3 Hz,
1H), 2.25 (dt, J = 13.8, 2.7 Hz, 1H), 1.86 (t, J = 12.0 Hz, 1H),
1.85–1.77 (m, 1H), 1.63–1.57 (bs, 2H), 1.51 (t, J = 13.0 Hz, 1H),
1.38–1.17 (m, 2H), 1.00 (s, 3H), 0.77 (s, 3H). 13C-NMR
(100 MHz, CDCl3) δ(ppm): 171.9 (C), 171.5 (C), 74.6 (CH), 61.5
(CH2), 54.9 (C), 53.0 (CH2), 52.9 (CH2), 38.6 (CH), 38.3 (C), 34.7
(CH2), 32.2 (CH2), 31.7 (CH2), 24.9 (CH3), 12.2 (CH3). HRMS
(TOF MS ES+) m/z calcd for C14H24O6Na [M + Na]
+: 311.1465,
found: 311.1468.
Compounds 7 and 8. Compounds 7 and 8 were isolated as a
mixture in a 7/8 ratio of 1.6/1. Colorless oil; 53% yield. (Com-
pounds 7 (33% yield) and 8 (20% yield) were not separated.)
1H-NMR (400 MHz, CDCl3) δ(ppm): 5.89 (dd, J = 18.7, 7.0 Hz,
1H, 7), 5.67 (d, J = 18.7 Hz, 1H, 7), 3.75 (s, 3H, 7), 3.74 (s, 3H,
8), 3.71 (s, 3H), 3.40 (dd, J = 12.0, 4.1 Hz, 1H, 7), 3.34 (dd, J =
12.0, 4.0 Hz, 1H, 8), 2.37 (ddd, J = 12.6, 4.0, 2.2 Hz, 1H), 2.11
(dt, J = 12.8, 2.0 Hz, 1H), 1.96–1.74 (m, 3H), 1.60–1.50 (m, 1H,
8), 1.40 (t, J = 13.0 Hz, 1H, 8), 0.99 (s, 3H, 8), 0.95 (s, 3H, 7),
0.94–0.80 (m, 2H, 8) 0.77 (s, 3H, 7), 0.73 (s, 3H, 8), 0.72–0.61
(m, 1H, 8), 0.35–0.20 (m, 1H, 8), 0.04 (s, 9H, 7), 0.03 (s, 9H, 8).
13C-NMR (100 MHz, CDCl3) δ(ppm): 172.2 (C), 171.9 (C), 171.6
(C), 171.5 (C), 145.2 (CH, 7), 132.6 (CH, 7), 74.6 (CH), 74.4 (CH),
54.9 (C), 54.8 (C), 53.0 (CH3), 52.9 (CH3), 52.8 (CH3), 52.7 (CH3),
49.1 (CH), 45.7 (CH), 38.7 (C), 38.1 (C), 34.8 (CH2), 34.6 (CH2),
31.7 (CH2), 31.2 (CH2), 25.6 (CH3), 25.0 (CH3), 23.2 (CH2, 8),
15.1 (CH2, 8), 12.4 (CH3), 12.1 (CH3), −1.6 (CH3), −1.1 (CH3).
HRMS (TOF MS ES+) m/z calcd for C17H30O5Si [M]
+: 342.1863,
found: 342.1867. HRMS for compound 8 was not found.
Compound 10. Colorless oil; 53% yield. 1H-NMR (500 MHz,
CDCl3) δ(ppm): 5.74–5.62 (m, 1H), 5.06 (d, J = 16.1 Hz, 1H),
5.05 (d, J = 11.3 Hz, 1H), 3.71 (s, 6H), 3.41 (d, J = 10.9 Hz, 1H),
3.36 (d, J = 10.9 Hz, 1H), 2.59–2.49 (m, 1H), 2.43 (d, J = 14.2
Hz, 1H), 2.42–2.37 (m, 1H), 2.28 (t, J = 12.8 Hz, 1H), 2.06 (d, J =
14.2 Hz, 1H), 0.82 (s, 3H); NOE-diff. experiment: proton ir-
radiated, (NOEs observed): H3-8, (H-2b, H2-9, H-6), H-6, (H2-5,
H-4, H3-8), H-4, (H-6, H2-7, H2-5, H2-9).
13C-NMR (125 MHz,
CDCl3) δ(ppm): 173.5 (C), 172.9 (C), 137.3 (CH), 116.7 (CH2),
69.3 (CH2), 57.9 (C), 53.1 (CH3), 52.9 (CH3), 48.1 (CH), 46.9 (C),
43.5 (CH2), 38.5 (CH2), 19.3 (CH3). HRMS (TOF MS ES+) m/z
calcd for C13H20O5Na [M + Na]
+: 279.1202, found: 279.1200.
Compound 12. Compound 12 was obtained as a 7/3 mixture
of cis/trans diastereoisomers. Colorless oil; 60% yield. 1H-NMR
(300 MHz, CDCl3) δ(ppm): 5.85 (ddd, J = 17.3, 10.2, 8.5 Hz, 1H,
cis-12), 5.70 (ddd, J = 17.4, 10.1, 8.1 Hz, 1H, trans-12), 5.09 (d, J
= 16.6 Hz, 1H, cis-12), 5.05 (d, J = 8.6 Hz, 1H, cis-12), 5.07–4.95
(m, 2H, trans-12), 3.72 (bs, 6H), 3.68–3.52 (m, 2H, trans-12),
3.61 (dd, J = 11.1, 6.4 Hz, 1H, cis-12), 3.48 (dd, J = 11.1, 6.3 Hz,
1H, cis-12), 2.88–2.74 (m, 1H), 2.54–2.23 (m, 3H), 2.19–1.98 (m,
2H). 13C-NMR (75 MHz, CDCl3) δ(ppm): 173.1 (C), 173.0 (C),
172.9 (C), 172.0 (C), 140.3 (CH), 137.8 (CH), 116.1 (CH2), 115.9
(CH2), 64.4 (CH2), 63.2 (CH2), 59.2 (C), 58.8 (C), 53.0 (CH3),
52.9 (CH3), 47.3 (CH), 46.5 (CH), 45.1 (C), 44.9 (CH), 40.9
(CH2), 39.1 (CH2), 37.1 (CH2), 36.5 (CH2). HRMS (TOF MS ES+)
m/z calcd for C12H18O5Na [M + Na]
+: 265.1046, found:
265.1054. Compound 12 was oxidized to simplify the 1H-NMR
spectrum and confirm the ratio of diastereomers obtained. See
ESI† for further details.
Compounds 14 and 15. Compounds 14 and 15 were both
obtained as a mixture of diastereoisomers. Yellowish oil; 55%
yield. Compounds 14 and 15 were not separated. 1H-NMR
(400 MHz, CDCl3) δ(ppm): 5.90–5.73 (m, 1H, 14 or 15),
5.63–5.48 (m, 1H, 14 or 15), 5.10–4.96 (m, 2H), 3.82–3.72 (m,
1H, 14 or 15), 3.73 (bs, 3H, 14 or 15), 3.71 (bs, 3H), 3.69 (bs,
3H, 14 or 15), 3.37–3.26 (m, 1H, 14 or 15), 2.61–2.39 (m, 2H),
2.35–2.14 (m, 2H), 2.08–1.96 (m, 1H), 1.93–1.72 (m, 1H),
1.69–1.54 (m, 1H), 1.15 (d, J = 4.3 Hz, 3H, 15), 0.96 (d, J =
6.0 Hz, 3H, 14). HRMS (TOF MS ES+) m/z calcd for C13H20O5Na
[M + Na]+: 279.1202, found: 279.1210. The mixture of com-
pounds 14 and 15 was oxidized to simplify the 1H-NMR spec-
trum and confirm both compounds and dr obtained. See ESI†
for further details.
Compound 17. Colorless oil; 50% yield. 1H-NMR (400 MHz,
CDCl3) δ(ppm): 5.29 (s, 1H), 5.02 (s, 1H), 4.54 (s, 2H), 4.20 (q,
J = 7.1 Hz, 2H), 3.75 (s, 3H), 3.70 (s, 3H), 3.42 (dd, J = 12.0,
4.0 Hz, 1H), 2.39 (ddd, J = 13.2, 4.0, 2.3 Hz, 1H), 2.14 (dt, J =
13.7, 2.6 Hz, 1H), 2.00 (t, J = 14.2 Hz, 1H), 1.91–1.85 (m, 1H),
1.84 (t, J = 14.2 Hz, 1H), 1.31 (t, J = 7.1 Hz, 3H), 0.95 (s, 3H),
0.87 (s, 3H); NOE-diff. experiment: proton irradiated (NOEs
observed): H-3, (H-2a, H-5). 13C-NMR (100 MHz, CDCl3)
δ(ppm): 171.7 (C), 171.3 (C), 155.1 (C), 143.5 (C), 115.3 (CH2),
74.7 (CH), 71.1 (CH2), 64.2 (CH2), 54.9 (C), 53.0 (CH3), 52.8
(CH3), 44.6 (CH), 39.1 (C), 34.6 (CH2), 32.5 (CH2), 25.7 (CH3),
14.4 (CH3), 12.7 (CH3). HRMS (TOF MS ES+) m/z calcd for
C18H28O8Na [M + Na]
+: 395.1676, found: 395.1668.
Compound 19. Colorless oil; 54% yield. 1H-NMR (500 MHz,
CDCl3) δ(ppm): 7.31 (t, J = 7.3 Hz, 2H), 7.25–7.20 (m, 1H), 7.14
(dd, J = 8.3, 1.4 Hz, 2H), 5.43 (ddd, J = 17.5, 10.4, 7.1 Hz, 1H),
4.83 (d, J = 16.1 Hz, 1H), 4.81 (d, J = 9.4 Hz, 1H), 3.86 (td, J =
11.2, 4.7 Hz, 1H), 3.82 (s, 3H), 3.75 (s, 3H), 2.74 (ddd, J = 13.1,
4.7, 2.2 Hz, 1H), 2.55–2.44 (m, 2H), 2.27 (dd, J = 11.2, 10.6 Hz,
1H), 1.82 (dd, J = 13.1, 11.2 Hz, 1H), 1.74 (dd, J = 13.4, 12.2 Hz,
1H). NOE-diff. experiment: proton irradiated (NOEs observed):
H-7 (H2-8, H-4, H-6b), H-4 (H-2b, H-6b), H-3 (H2-2, H-5).
13C-NMR (125 MHz, CDCl3) δ(ppm): 171.8 (C), 171.4 (C), 140.1
(C), 139.6 (CH), 128.8 (CH), 127.3 (CH), 115.5 (CH2), 71.2 (CH),
57.4 (CH), 54.8 (C), 53.1 (CH3), 52.9 (CH3), 42.3 (CH), 38.1
(CH2), 36.6 (CH2). HRMS (TOF MS ES+) m/z calcd for
C18H22O5Na [M + Na]
+: 341.1359, found: 341.1359.
Compound 21. Colorless oil; 58% yield. 1H-NMR (500 MHz,
CDCl3) δ(ppm): 5.64 (ddd, J = 17.2, 10.1, 9.0 Hz, 1H), 5.10 (dd,
J = 17.2, 1.5 Hz, 1H), 5.03 (dd, J = 10.1, 1.5 Hz, 1H), 3.75 (s,
3H), 3.69 (s, 3H), 3.62 (dd, J = 11.0, 4.4 Hz, 1H), 3.40 (dd, J =
11.0, 6.1 Hz, 1H), 2.41 (ddd, J = 13.5, 6.0, 3.2 Hz, 1H),
2.35–2.27 (m, 1H), 2.10–1.96 (m, 1H), 1.84 (ddd, J = 13.6, 7.1,
3.9 Hz, 1H), 1.71 (td, J = 13.6, 3.9 Hz, 1H), 1.63–1.53 (m, 1H),
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1.39–1.14 (m, 2H). 2D-NOESY spectra observed: H-5 (H-9), H-5
(H-6), H-5 (H-3a), H-4 (H2-11), H-4 (H-3b).
13C-NMR (125 MHz,
CDCl3) δ(ppm): 172.69 (C), 171.52 (C), 141.76 (CH), 115.87
(CH2), 66.33 (CH2), 54.90 (C), 52.85 (CH3), 52.67 (CH3), 43.34
(CH), 41.80 (CH), 37.44 (CH2), 30.73 (CH2), 25.59 (CH2). HRMS
(TOF MS ES+) m/z calcd for C13H20O5Na [M + Na]
+: 279.1201,
found: 279.1215.
Compound 23. White solid; m.p. 121–123 °C. 76% yield.
1H-NMR (500 MHz, CDCl3) δ(ppm): 7.65 (d, J = 8.3 Hz, 2H),
7.33 (d, J = 8.3 Hz, 2H), 5.58 (ddd, J = 17.1, 10.4, 8.6 Hz, 1H),
5.12 (d, J = 10.4 Hz, 1H), 5.09 (d, J = 17.1 Hz, 1H), 3.65 (ddd, J =
11.2, 4.8, 1.7 Hz, 1H), 3.54 (dd, J = 10.5, 4.8 Hz, 1H), 3.46 (ddd,
J = 11.8, 4.2, 1.7 Hz, 1H), 2.44 (s, 3H), 2.35 (dd, J = 23.9,
11.4 Hz, 2H), 2.21–2.14 (m, 1H), 0.97 (s, 3H), 0.65 (s, 3H).
NOE-diff. experiment: proton irradiated (NOEs observed): H-5
(H-6, H-3), H-3 (H-2, H-5). 13C-NMR (125 MHz, CDCl3) δ(ppm):
143.7 (C), 134.3 (CH), 129.8 (CH), 127.7 (CH), 118.7 (CH2), 74.2
(CH), 49.2 (CH), 47.4 (CH2), 46.0 (CH2), 37.1 (C), 25.2 (CH3),
21.7 (CH3), 12.3 (CH3). HRMS (TOF MS ES+) m/z calcd for
C16H24NO3S [M + H]
+: 310.1471, found: 310.1481.
Compound 25. Colorless oil; 74% yield. 1H-NMR (400 MHz,
CDCl3) δ(ppm): 7.70 (d, J = 8.2 Hz, 2H), 7.31 (d, J = 8.2 Hz, 2H),
5.51 (ddd, J = 17.1, 10.3, 8.5 Hz, 1H), 5.06 (d, J = 10.3 Hz, 1H),
5.00 (d, J = 17.1 Hz, 1H), 3.49 (dd, J = 9.9, 8.0 Hz, 1H), 3.34 (dd,
J = 17.9, 10.9 Hz, 2H), 3.29 (d, J = 9.8 Hz, 1H), 3.13 (t, J = 9.9
Hz, 1H), 3.06 (d, J = 9.8 Hz, 1H), 2.57 (dd, J = 17.1, 8.0 Hz, 1H),
2.42 (s, 3H), 0.71 (s, 3H). NOE-diff. experiment: proton ir-
radiated (NOEs observed): H-6 (H-5, H2-9, H3-8), H-4 (H-6, H2-
7, H-5, H2-9), H3-8 (H-2, H2-9, H-6).
13C-NMR (100 MHz, CDCl3)
δ(ppm): 143.6 (C), 134.3 (CH), 129.7 (CH), 127.5 (CH), 118.4
(CH2), 67.0 (CH2), 56.6 (CH2), 51.0 (CH2), 47.1 (CH), 46.4 (C),
21.6 (CH3), 16.9 (CH3). HRMS (TOF MS ES+) m/z calcd for
C15H22NO3S [M + H]
+: 296.1314, found: 296.1326.
Compound trans-27. Vitreous solid; 39% yield. 1H-NMR
(500 MHz, CDCl3) δ(ppm): 8.14 (dd, J = 8.5, 1.2 Hz, 2H), 8.02
(dd, J = 8.5, 1.2 Hz, 2H), 7.74 (dd, J = 15.3, 7.2 Hz, 2H), 7.63
(dd, J = 15.3, 7.2 Hz, 4H), 5.70 (ddd, J = 17.2, 10.9, 8.3 Hz, 1H),
5.14 (d, J = 10.9 Hz, 1H), 5.13 (d, J = 17.2 Hz, 1H), 4.27 (d, J =
11.4 Hz, OH), 3.60 (ddd, J = 11.4, 4.9, 2.0 Hz, 1H), 2.92 (dd, J =
16.5, 4.9 Hz, 1H), 2.81 (ddd, J = 12.4, 8.3, 3.8 Hz, 1H), 2.52 (d,
J = 18.6 Hz, 1H), 2.49 (t, J = 13.0 Hz, 1H), 2.18 (ddd, J = 15.7,
3.8, 1.7 Hz, 1H), 1.04 (s, 3H), 0.82 (s, 3H). NOE-diff. exper-
iment: proton irradiated, (NOEs observed): H-5, (H-7, H-6),
H-3, (H-2, H-6). 13C-NMR (125 MHz, CDCl3) δ(ppm): 137.47
(CH), 135.78 (C), 135.04 (CH), 134.94 (C), 134.84 (CH), 132.04
(CH), 131.75 (CH), 128.83 (CH), 128.79 (CH), 117.67 (CH2),
89.02 (C), 74.24 (CH), 40.32 (CH), 36.98 (C), 28.59 (CH2), 27.34
(CH2), 25.57 (CH3), 19.34 (CH3). HRMS (TOF MS ES+) m/z calcd
for C22H26O5S2Na [M + Na]
+: 457.1113, found: 457.1100
Compound cis-27. White solid; m.p. 153–156 °C. 32% yield.
1H-NMR (400 MHz, CDCl3) δ(ppm): 8.07 (d, J = 7.6 Hz, 2H),
8.02 (d, J = 7.6 Hz, 2H), 7.76–7.67 (m, 2H), 7.65–7.56 (m, 4H),
5.64 (ddd, J = 17.3, 10.8, 8.8 Hz, 1H), 5.11 (d, J = 10.8 Hz, 1H),
5.10 (d, J = 17.3 Hz, 1H), 4.24–4.09 (m, 1H), 2.68 (ddd, J = 12.5,
8.8, 3.8 Hz, 1H), 2.52–2.24 (m, 3H), 2.06–1.95 (m, 1H), 1.02 (s,
3H), 0.71 (s, 3H). NOE-diff. experiment: proton irradiated
(NOEs observed): H-5, (H-7, H-3, H-6), H-3, (H-5, H-2).
13C-NMR (100 MHz, CDCl3) δ(ppm): 137.0 (CH), 135.9 (C),
134.8 (CH), 134.6 (CH), 131.7 (CH), 131.3 (CH), 128.7 (CH),
117.7 (CH2), 88.6 (C), 73.0 (CH), 45.8 (CH), 37.6 (C), 30.4 (CH2),
27.0 (CH2), 25.3 (CH3), 11.7 (CH3). HRMS (TOF MS ES+) m/z
calcd for C22H26O5S2Na [M + Na]
+: 457.1113, found: 457.1092.
Compound 29. Colorless oil; 62% yield. 1H-NMR (400 MHz,
CDCl3) δ(ppm): 5.30 (s, 1H), 5.07 (s, 1H), 4.54 (s, 2H), 4.22 (q,
J = 7.1 Hz, 2H), 3.87 (dd, J = 12.2, 4.2 Hz, 1H), 3.77 (s, 3H), 3.71
(s, 3H), 3.60 (d, J = 10.8 Hz, 1H), 3.38 (d, J = 10.8 Hz, 1H), 2.42
(ddd, J = 13.2, 4.1, 2.2 Hz, 1H), 2.19 (dt, J = 13.5, 2.7 Hz, 1H),
2.16–2.12 (m, 1H), 2.01 (t, J = 13.1 Hz, 1H), 1.95 (t, J = 12.5 Hz,
1H), 1.32 (t, J = 7.1 Hz, 3H), 0.92 (s, 3H). 2D-NOESY spectra
observed: H-3 (H-2a), H-3 (H-5), H-3 (H-11), H-5 (H-11).
13C-NMR (100 MHz, CDCl3) δ(ppm): 171.6 (C), 171.2 (C), 155.2
(C), 143.3 (C), 116.1 (CH2), 71.2 (CH), 71.1 (CH2), 68.3 (CH2),
64.4 (CH2), 54.7 (C), 53.1 (CH3), 52.9 (CH3), 43.1 (C), 39.0 (CH),
34.2 (CH2), 32.4 (CH2), 14.4 (CH3), 9.3 (CH3). HRMS (TOF MS
ES+) m/z calcd for C18H28O9Na [M + Na]
+: 411.1625, found:
411.1627.
Compound 31. Yellowish oil; 73% yield. 1H-NMR (400 MHz,
CDCl3) δ(ppm): 5.69 (ddd, J = 17.2, 10.2, 8.8 Hz, 1H), 5.09 (d,
J = 17.2 Hz, 1H), 5.05 (d, J = 10.2 Hz, 1H), 3.75 (s, 3H), 3.70 (s,
3H), 3.34 (d, J = 11.0 Hz, 1H), 3.29 (d, J = 11.0 Hz, 1H),
2.30–2.20 (m, 2H), 2.15 (ddd, J = 11.0, 3.5, 2.4 Hz, 1H), 1.89
(td, J = 13.7, 3.5 Hz, 1H), 1.82 (t, J = 13.0 Hz, 1H), 1.50 (td, J =
13.9, 3.7 Hz, 1H), 1.35 (dt, J = 13.9, 3.6 Hz, 1H), 0.84 (s, 3H).
NOE-diff. experiment: proton irradiated, (NOEs observed): H-7,
(H-8, H3-9), H2-10, (H-5, H3-9), H3-9, (H-7, H2-10).
13C-NMR
(100 MHz, CDCl3) δ(ppm): 172.7 (C), 171.5 (C), 139.3 (CH),
116.4 (CH2), 71.8 (CH2), 55.0 (C), 52.8 (CH3), 52.6 (CH3), 42.8
(CH), 37.3 (C), 32.4 (CH2), 31.5 (CH2), 26.4 (CH2), 14.9 (CH3).
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